|
|
||||||||||||||
|
|
|||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BREAST PATHOLOGY |
Molecular & Cellular Pathology, School of Medicine, University of Queensland; The Queensland Institute of Medical Research; and Queensland Health Pathology Services, The Royal Brisbane & Womens Hospital, Brisbane, Australia
Correspondence to:
Professor S R Lakhani, Molecular and Cellular Pathology, School of Medicine, The University of Queensland, Mayne Medical School, Herston Rd, Herston QLD 4006, Australia; s.lakhani{at}uq.edu.au
"Basal" breast cancers are dominating the breast research literature at present and pathologists are under increasing pressure to evaluate for such a phenotype by their surgical and oncological colleagues. There is also much confusion about how to assess cancers, which immunohistochemical markers to use, what meaning and benefit this provides, and what the surgeons and oncologists will do with the information. Much remains to be done to answer all these questions but here we try to shed light on some of the issues and suggest what is still to come.
This article has been cited by other articles:
![]() |
N. Dourdin, B. Schade, R. Lesurf, M. Hallett, R. J. Munn, R. D. Cardiff, and W. J. Muller Phosphatase and Tensin Homologue Deleted on Chromosome 10 Deficiency Accelerates Tumor Induction in a Mouse Model of ErbB-2 Mammary Tumorigenesis Cancer Res., April 1, 2008; 68(7): 2122 - 2131. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
| Journal of Clinical Pathology | Molecular Pathology |